1. Home
  2. PZG vs PLYX Comparison

PZG vs PLYX Comparison

Compare PZG & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paramount Gold Nevada Corp.

PZG

Paramount Gold Nevada Corp.

HOLD

Current Price

$1.45

Market Cap

132.1M

ML Signal

HOLD

Logo Polaryx Therapeutics Inc. Common Stock

PLYX

Polaryx Therapeutics Inc. Common Stock

N/A

Current Price

$2.08

Market Cap

112.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PZG
PLYX
Founded
1992
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.1M
112.7M
IPO Year
2015
2025

Fundamental Metrics

Financial Performance
Metric
PZG
PLYX
Price
$1.45
$2.08
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
494.7K
103.1K
Earning Date
05-11-2026
05-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
77.53
EPS
N/A
N/A
Revenue
$330,259.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$1.86
52 Week High
$2.70
$9.18

Technical Indicators

Market Signals
Indicator
PZG
PLYX
Relative Strength Index (RSI) 59.51 43.61
Support Level $1.07 $2.03
Resistance Level $1.46 $2.39
Average True Range (ATR) 0.09 0.25
MACD 0.02 0.02
Stochastic Oscillator 58.74 16.89

Price Performance

Historical Comparison
PZG
PLYX

About PZG Paramount Gold Nevada Corp.

Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold, frost project, other non-material, and others.

About PLYX Polaryx Therapeutics Inc. Common Stock

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Share on Social Networks: